Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

Full NameDr Selinda Orr

Wellcome-Wolfson Institute for Experimental Medicine

Queen's University Belfast

Webpage:qub.ac.uk

Email hidden; Javascript is required.

Research Fields
  • infectious disease and the immune system
Postgrad Medical Specialties
  • Medicine
Medical Subspecialties
  • Infectious diseases
  • Immunology
My Work

The research in my lab is focused on understanding how the immune system responds to different fungal pathogens including Candida and Aspergillus with the aim of 1) identifying ways to manipulate the immune response to improve patient outcome or 2) to identify factors to stratify patient groups into high or low risk of developing life threatening invasive fungal infections. We recently generated a number of novel models to examine the collective role of various pathogen recognition receptors (PRRs). We are investigating how the receptors function individually, where/when they are redundant, where/when/how they collaborate to induce a robust immune response. In addition we are comparing the immune response to different fungal spp. with varying pathogenicities. This information is required in order to develop novel vaccine and immunotherapy approaches. We are also examining polymorphisms in PRRs and immune response to Aspergillus in “at risk” patient groups in order to identify factors which could be used to stratify these “at risk” patients into low and high risk patients for developing invasive aspergillosis. This would allow targeted prophylactic therapies for the high risk patients.

Scroll to Top